Moreover, the effective dosage of CD47 antagonists may require adjustments in scenarios where tumor cells express both SIRPα and thrombospondin-1 (TSP-1), both of which disrupt the CD47-SIRPα interaction. This evidence concerns the gene CD47 and neoplasm.